◈ Madison Heights, MI · 2022

WhereScienceMeets Hope.

Veritas Clinical Research exists for one reason: to get it right. We conduct clinical trials with an uncompromising dedication to honest science and ethical principles — because the future of medicine depends on research the world can trust. No shortcuts. No spin. Just rigorous, transparent, patient-centered research that moves medicine forward.

Anatomically detailed pair of human lungs, breathing
Years of servicesince 2022

More than 20 years of pulmonary medicine behind every protocol.

◈ Our method

A rhythm of rigor — measured across five years of follow-up.

Every protocol we run anchors on the same three disciplines: deep phenotyping at baseline, standardized spirometry on every visit, and longitudinal follow-up that lasts years after the last dose. The chart shows mean FEV₁ across a Veritas Clinical Research cohort vs. standard-of-care comparators.

See our published methodology →
N · 412 volunteersMean Δ FEV₁ · +0.14 LExacerbations · −42%Published · AJRCCM · 2024P-value · < 0.001

Thirteen trials. One enrolling now.

Our full portfolio as a Principal Investigator site — asthma, COPD, IPF, and bronchiectasis, from Phase II to Phase IV. The recruiting study accepts direct volunteer referrals; screening is free and travel is reimbursed.
RecruitingNCT07190209

Lunsekimig vs. placebo in inadequately controlled eosinophilic COPD

Phase IIICOPD
Details →
Active · not recruitingNCT06748053

Dose-finding study of an anti-TSLP antibody (GSK5784283) in uncontrolled asthma

Phase IIAsthma
Details →
Active · not recruitingNCT05748600

Dexpramipexole in adolescents and adults with eosinophilic asthma

Phase IIIAsthma
NCT ↗
Active · not recruitingNCT06208306

Long-term safety and tolerability of itepekimab in COPD

Phase IIICOPD
NCT ↗
Active · not recruitingNCT03953300

Benralizumab airway remodeling study in severe eosinophilic asthma

Phase IVAsthma
NCT ↗
Active · not recruitingNCT06372496

FF/UMEC/VI vs. non-Ellipta usual-care ICS-LABA in uncontrolled asthma

Phase IVAsthma
NCT ↗
CompletedNCT04718389

Depemokimab (GSK3511294) vs. mepolizumab or benralizumab in severe eosinophilic asthma

Phase IIIAsthma
NCT ↗
CompletedNCT04701983

Efficacy, safety, and tolerability of itepekimab (SAR440340/REGN3500) in COPD

Phase IIICOPD
NCT ↗
CompletedNCT05326412

Mechanistic study of itepekimab on airway inflammation in COPD

Phase IICOPD
NCT ↗
CompletedNCT06335303

BI 1819479 for improvement of lung function in idiopathic pulmonary fibrosis (IPF)

Phase IIIPF
NCT ↗
CompletedNCT06280391

Itepekimab (anti-IL-33 mAb) proof-of-concept in non-cystic-fibrosis bronchiectasis

Phase IIBronchiectasis
NCT ↗
TerminatedNCT05813288

Dexpramipexole in adolescents and adults with severe eosinophilic asthma (EXHALE-3)

Phase IIIAsthma
NCT ↗
TerminatedNCT06360094

BI 1839100 for cough in idiopathic or progressive pulmonary fibrosis

Phase IIIPF / PPF
NCT ↗
Dr. Franco Parodi, Principal Investigator at Veritas Clinical Research
◈ Principal investigator

Dr. Franco Parodi

EducationUniversidad de San Martin de Porres, Lima, Peru · Henry Ford Hospital, Detroit — Internal Medicine Residency & Fellowship in Pulmonary Diseases and Critical Care Medicine
MembershipsFellow of the American Academy of Chest Physicians · Member of the Association of Clinical Research Professionals
AppointmentsAssociate Professor of Medicine, Michigan State University College of Osteopathic Medicine · Associate Program Director, Fellowship in Pulmonary & Critical Care Medicine, Henry Ford Warren Hospital, MI
At Veritas Clinical Research, our work begins and ends with people. We are a clinical research site dedicated to advancing the future of medicine through carefully conducted clinical trials — driven not by shortcuts, but by a genuine commitment to truth and ethical responsibility. We believe every participant in our studies deserves transparency, respect, and care, and that every sponsor deserves research they can trust. By holding ourselves to the highest standards of scientific and moral integrity, we help bring tomorrow's most promising therapies safely and confidently into the world.
Franco Parodi MD
Founder and PI
◈ What being a volunteer feels like

Four careful steps.

We don't believe in mystery. Here is exactly what happens from the first phone call to the last follow-up visit — with the option to stop at any step, no questions asked.

i

Conversation, not commitment

A 20-minute call with a Veritas Clinical Research coordinator. We describe the trial, you describe your story, and we check whether there's a mutual fit.

Day 01
ii

Screening visit

Spirometry, bloodwork, medication review. You leave with a full copy of your pulmonary workup — whether you enroll or not.

Week 01
iii

Treatment phase

Regular visits on a predictable cadence. Our coordinator is one text away, every weekday.

Weeks 02–48
iv

Long-term follow-up

Optional annual visits up to five years, so the science — and your health — keeps moving forward together.

Years 1–5
I came in thinking I was donating my lungs to science. I left with a team who called me on Christmas Eve to check how I was breathing.
Marta R., 68Volunteer · IPF cohort, 2022–2024
◈ Start here

Let's breathe forward.

Whether you're a pulmonologist with a patient to refer, a sponsor evaluating sites, or a volunteer considering a trial — a single conversation starts the whole thing.

See if you qualify →Talk to a coordinator